ReviewFrontiers in immunology2019
Getting to the Heart of the Matter: The Role of Regulatory T-Cells (Tregs) in Cardiovascular Disease (CVD) and Atherosclerosis.
Review in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 86 citations in OpenAlex.
- CT-Based Thymic Morphology as an Imaging Surrogate of Immune Ageing and Its Association with Coronary Artery Calcification-A Hypothesis-Generating Observational Study.Biomedicines · 2026Article
- Rosuvastatin Upregulates RCOR1 to Repress C10ORF10 Transcription and Alleviate Oxidative Stress and Plaque Formation in Atherosclerosis.The Kaohsiung journal of medical sciences · 2026Article
- Mitochondria-Associated Endoplasmic Reticulum Membrane Biomarkers in Coronary Heart Disease and Atherosclerosis: A Transcriptomic and Mendelian Randomization Study.Current issues in molecular biology · 2026Article
- Regulatory T cells in homeostasis and disease: molecular mechanisms and therapeutic potential.Signal transduction and targeted therapy · 2025Review
- Review
- The Dual Role of Conjugated Linoleic Acid in Obesity and Metabolic Disorders.Food science & nutrition · 2025Review
- Lymphocyte Subset Imbalance in Cardiometabolic Diseases: Are T Cells the Missing Link?International journal of molecular sciences · 2025Review
- Integrated Analysis of Ferroptosis- and Cellular Senescence-Related Biomarkers in Atherosclerosis Based on Machine Learning and Single-Cell Sequencing Data.Journal of inflammation research · 2025Article
- Unraveling the Causal Links Between Immune Cells, Lipids, and Cardiovascular Diseases: Insights from Mendelian Randomization.Global heart · 2025Article
- Article
- Regulatory T cells: a promising new therapeutic target in ventricular remodeling after myocardial infarction.Frontiers in immunology · 2025Review
- Thrombo-inflammation linking androgen suppression with cardiovascular risk in patients with prostate cancer.Cardio-oncology (London, England) · 2024Review
- Salvianolic acid A alleviates HScientific reports · 2024Article
- Exercise immunology: Novel insights.Journal of sport and health science · 2024Article
- Identification of a non-canonical chemokine-receptor pathway suppressing regulatory T cells to drive atherosclerosis.Nature cardiovascular research · 2024Article
- Integrative single-cell and bulk RNA-seq analyses identify CD4Frontiers in immunology · 2024Article
- Regulation of vascular remodeling by immune microenvironment after the establishment of autologous arteriovenous fistula in ESRD patients.Frontiers in immunology · 2024Review
- Regulatory T cells and macrophages in atherosclerosis: from mechanisms to clinical significance.Frontiers in immunology · 2024Review
- Causal relationship between immune cells and risk of myocardial infarction: evidence from a Mendelian randomization study.Frontiers in cardiovascular medicine · 2024Article
- Immune cell-mediated features of atherosclerosis.Frontiers in cardiovascular medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular diseases (CVD) are the leading cause of mortality worldwide. Atherosclerosis is directly associated with CVD and is characterized by slow progressing inflammation which results in the deposition and accumulation of lipids beneath the endothelial layer in conductance and resistance arteries. Both chronic inflammation and disease progression have been associated with several risk factors, including but not limited to smoking, obesity, diabetes, genetic predisposition, hyperlipidemia, and hypertension. Currently, despite increasing incidence and significant expense on the healthcare system in both western and developing countries, there is no curative therapy for atherosclerosis. Instead patients rely on surgical intervention to avoid or revert vessel occlusion, and pharmacological management of the aforementioned risk factors. However, neither of these approaches completely resolve the underlying inflammatory environment which perpetuates the disease, nor do they result in plaque regression. As such, immunomodulation could provide a novel therapeutic option for atherosclerosis; shifting the balance from proatherogenic to athero-protective. Indeed, regulatory T-cells (Tregs), which constitute 5-10% of all CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.